The following listing of claims replaces all prior versions and listings of claims in the application.

1. (Currently Amended) A method of ameliorating chronic allograft rejection in a human or animal allograft recipient comprising administering to the recipient in need of such treatment, in combination, a therapeutically effective amount of cyclosporin at least once weekly and a therapeutically effective amount ~~2-clorodeoxyadenosine~~ of 2-chlorodeoxyadenosine at least once weekly.

2. (Original) The method according to claim 1 wherein the therapeutically effective amount of cyclosporin is between about seven and about 224 times the amount by mass of 2-chlorodeoxyadenosine.

3. (Original) The method according to claim 1 wherein the therapeutically effective amount of cyclosporin is between about 1 mg and about 16 mg per kilogram of recipient body mass per day.

4. (Original) The method according to claim 3 wherein the dosing regime for cyclosporin is between about 7 and about 112 mg per kilogram of recipient body mass per week.

5. (Original) The method according to claim 4 wherein the dosing regime for cyclosporin is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.

6. (Original) The method according to claim 5 wherein the daily dose is divided into two equal daily doses.

7. (Currently Amended) The method according to claim 1 wherein the therapeutically effective amount of ~~2-clorodeoxyadenosine~~ 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week.

8. (Currently Amended) The method according to claim 1 wherein the therapeutically

effective amount of ~~2-clorodeoxyadenosive~~ 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

9. (Original) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

10. (Currently Amended) The method according to claim 7 wherein the dosing regime for ~~2-chlorodexyadenosine~~ 2-chlorodeoxyadenosine is about 3 mg per kilogram of recipient body mass about every three weeks.

11. (Original) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is 1.5 mg per kilogram of recipient body mass about every three weeks.

12. (Original) The method according to claim 1 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.

13. (Currently Amended) A method of preventing ~~ameliorating~~ chronic allograft rejection in ~~a human or animal~~ an allograft recipient comprising administering to an allograft recipient a therapeutically effective amount of cyclosporin at least once weekly and a therapeutically effective amount of ~~2-clorodeoxyadenosine~~ 2-chlorodeoxyadenosine at least once weekly.

14. (Currently Amended) The method according to ~~claim 12~~ claim 13 wherein the therapeutically effective amount of cyclosporin is between about 2 and about 224 times the amount by weight of 2-chlorodeoxyadenosine.

15. (Currently Amended) The method according to claim 13 wherein the therapeutically effective amount of cyclosporin is between about 1 mg and about 16 mg per kilogram of recipient body mass per day administered daily.

16. (Original) The method according to claim 13 wherein the dosing regime for cyclosporin is between about 7 and about 112 mg per kilogram of recipient body mass per week.

17. (Original) The method according to claim 16 wherein the dosing regime for cyclosporin is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.

18. (Original) The method according to claim 17 wherein the daily dose is divided into two equal daily doses.

19. (Currently Amended) The method according to claim 13 wherein the therapeutically effective amount of ~~2-clorodeoxyadenosine~~ 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week.

20. (Currently Amended) The method according to claim 13 wherein the therapeutically effective amount of ~~2-chlorodeoxyadenosive~~ 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

21. (Original) The method according to claim 20 wherein the dosing regime for 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

22. (Currently Amended) The method according to claim 20 wherein the dosing regime for ~~2-chlorodexyadenosine~~ 2-chlorodeoxyadenosine is about 3 mg per kilogram of recipient body mass about three weeks.

23. (Original) The method according to claim 20 wherein the dosing regime for 2-chlorodeoxyadenosine is 1.5 mg per kilogram of recipient body mass about every three weeks.

24. (Original) The method according to claim 13 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.

25. (Currently Amended) A pharmaceutical composition suitable for treating chronic allograft rejection comprising a therapeutically effective amount of cyclosporin, a therapeutically effective amount of 2-chlorodeoxyadenosine and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein the cyclosporin is present in an amount between about 2 and about 224 times

the amount by mass of 2-chlorodeoxyadenosine.

26. (Currently Amended) The pharmaceutical composition according to claim 25 wherein the ~~therapeutically effective amount of~~ cyclosporin is present in an amount between about [[2]] 5 and about [[224]] 10 times the amount by mass of 2-chlorodeoxyadenosine.

27. (Original) The pharmaceutical composition according to claim 25 wherein the therapeutically effective amount of cyclosporin is between about 1 mg and about 16 mg per kilogram of recipient body mass per day.

28. (Currently Amended) The pharmaceutical composition according to claim 25 wherein the therapeutically effective amount of ~~2-clorodeoxyadenosine~~ 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week.

29. (Currently Amended) The pharmaceutical composition according to claim 25 wherein the therapeutically effective amount of ~~2-chlorodeoxyadenosive~~ 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.

30. (Original) The pharmaceutical composition according to claim 25 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.

31. (Currently Amended) A method of preventing chronic allograft rejection in a human or animal allograft recipient comprising administering to the recipient the pharmaceutical composition according to claim 25 at least once a week.

32. (Currently Amended) A method of ameliorating chronic allograft rejection in a human or animal allograft recipient comprising administering to the recipient the pharmaceutical composition according to claim 25 at least once a week.

33. (Currently Amended) A method of preventing arterial atherosclerosis comprising administering the pharmaceutical composition according to claim 25 at least once a week.

34. (Original) The method according to claim 33 wherein the arterial atherosclerosis is associated with chronic allograft rejection in a human or animal allograft recipient.

35. (Currently Amended) A method of preventing chronic allograft rejection in animal or human allograft recipient comprising administering at least once a week to the recipient an amount of cyclosporin and an amount of ~~2-clorodeoxyadenosine~~ 2-chlorodeoxyadenosine sufficient to suppress the recipient's B-cell mediated response to the allograft.

36. (Original) The method according to claim 35 wherein the transplanted organ is a heart and the B-cell mediated response is one or a combination of mononuclear cell infiltration in the myocardium, myocardial fibrosis, and intimal proliferation of smooth muscle cells.